Lars Henrik Fugger

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Aiden Haghikia, Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
  • ,
  • Calliope A Dendrou, Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
  • ,
  • Ruth Schneider, Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
  • ,
  • Thomas Grüter, Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
  • ,
  • Thomas Postert, Neurologic Clinic, St Vincenz-Krankenhaus, Paderborn, Germany.
  • ,
  • Mike Matzke, Department of Neurology of the University of Magdeburg, Magdeburg, Germany.
  • ,
  • Heike Stephanik, Department of Neurology of the University of Magdeburg, Magdeburg, Germany.
  • ,
  • Lars Fugger
  • Ralf Gold, Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany. Electronic address: ralf.gold@rub.de.
Original languageEnglish
JournalLancet Neurology
Volume16
Issue2
Pages (from-to)104-106
Number of pages3
ISSN1474-4422
DOIs
Publication statusPublished - Feb 2017

    Research areas

  • Letter

See relations at Aarhus University Citationformats

ID: 115395242